Recruiting studies: Braf V600E Mutation Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NA · 45 location(s) · UNICANCER · NCT05639413 Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629 Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06653517 Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cance
Phase 2 · 1 location(s) · Federation Francophone de Cancerologie Digestive · NCT05706779 Special Drug Use-results Surveillance of Tafinlar/Mekinist
Phase N/A · 70 location(s) · Novartis Pharmaceuticals · NCT06262919

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.